Testing a New Immune Medicine After Esophageal Cancer Surgery

Plain-English translation of NCT06190639 on ClinicalTrials.gov ↗ · Source last updated January 2024 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This clinical trial is studying , a medication that helps your immune system fight cancer cells, as a treatment given after surgery for esophageal squamous cell carcinoma (a type of esophageal cancer). The study wants to see if giving this medication after surgery can help prevent the cancer from coming back in patients whose cancer has spread to lymph nodes.

Esophageal cancer that has spread to lymph nodes has a higher risk of returning even after surgery. Researchers believe that this medication might help lower that risk by keeping the immune system active against any remaining cancer cells.

Do you qualify?

You likely qualify if…

you have been diagnosed with esophageal squamous cell carcinoma that has spread to lymph nodes
you have had surgery to completely remove your esophageal cancer within 4 to 12 weeks before enrolling
your imaging tests (CT or MRI scans of your neck, chest, and abdomen) show no remaining cancer within 4 weeks before starting
you are in good enough health to tolerate the treatment, with normal or near-normal blood counts and organ function
you are 18 years or older and, if you are a woman who could become pregnant, you have a negative pregnancy test

You likely don't qualify if…

you have already received chemotherapy, radiation, immunotherapy, or other cancer treatments before surgery
you have an active autoimmune disease or condition that weakens your immune system
you are currently taking high-dose steroids or other immune-suppressing medications
you have a known HIV infection or AIDS
you have severe nerve damage or uncontrolled serious medical conditions

What participation looks like

You will receive injections of the medication once every 3 weeks over a planned treatment period. You will need to visit the study center regularly for these injections and for blood tests and imaging scans to monitor how well the medication is working and check for any side effects. The study team will carefully track your health throughout the trial.

AI-generated summary from trial data · Jun 16, 2026 · Not medical advice

Trial locations(1 site)

China

Zhejiang Cancer Hospital, Hangzhou, Zhejiang